Trial Profile

Multiple ascending dose study of a second generation ganaxolone formulation

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 26 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

16 Aug 2023 Status changed to recruiting, according to a Marinus Pharmaceuticals media release.
11 May 2023 According to a Marinus Pharmaceuticals media release, pending FDA feedback and agreement, trial is now expected to initiate in the third quarter of 2023 with preliminary data expected by year end 2023. The company is Planning to finalize clinical program design for Lennox-Gastaut syndrome in the first quarter of 2024, pending results of this trial.
22 Mar 2023 According to a Marinus Pharmaceuticals media release, the company expects to initiate this trial in the second quarter of 2023 and is planning to finalize the clinical program design for LGS in the second half of this year.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com